EcoOnline Celebrates Longstanding Partnership with Menzies Aviation, Driving Safety Culture Across the Globe
16.1.2025 09:00:00 CET | Business Wire | Press release
EcoOnline is proud to celebrate the continued success of its partnership with Menzies Aviation, the leading service partner to the world’s airports and airlines. Since 2019, EcoOnline has played a key role in enhancing the company’s MORSE (Menzies Operating Responsibly, Safely and Efficiently) system, driving safety culture and compliance across the company’s global network.
With a presence at more than 295 airports in over 65 countries, Menzies Aviation operates in high-risk environments, where safety is embedded in its DNA. As Malcolm Rae, Head of Risk Systems & Data at Menzies, reflects, “We influence safety from the moment passengers walk into an airport to when they leave. We live and breathe it day in, day out—not just in the risk and safety team, but every employee takes it extremely seriously.”
Technology That Drives Safety at Every Level
The longstanding collaboration with EcoOnline has enabled Menzies Aviation to implement a more efficient, data-driven approach to incident reporting, risk management and compliance tracking. Using EcoOnline’s advanced EHS (environment, health, and safety) solution—the technology behind Menzies’ MORSE reporting system—employees are empowered to quickly identify risks, make informed decisions, and proactively address safety risks in real time.
Since adopting EcoOnline’s platform in 2019, Menzies has seen remarkable improvements:
- 128% increase in employee hazard reporting.
- Serious personal injury reduced from 1.8 per 1,000 full-time employees in 2019 to 0.94 in 2022 and 0.7 in 2023.
"If you want to be an industry leader, you've got to know where your risks are, and that starts with empowering every employee to act. EcoOnline’s EHS platform equips everyone with the tools to report hazards and ensure our people go home safely," said Graham Cowing, Vice President of Safety Standards, Menzies Aviation.
Board Commitment to Safety
Safety at Menzies is championed at every level, from frontline workers to the boardroom. Graham commented:"Safety is a core value that starts with leadership. Every executive member is committed to getting involved, and initiatives like ‘Take 10 for Safety,’ where every board meeting begins with a safety-focused discussion, are supported by real-time dashboards from EcoOnline. These insights keep safety central to decision-making and drive accountability across the organisation."
MORSE: A system, culture and celebration
Menzies’ approach to safety is defined by its MORSE cultural mindset, MORSE safety systems, and immersive bi-annual MORSE Week events. Its most recent MORSE Week, which took place from 28 October – 1 November 2024 focused on emergency response planning, offering tools, support, and guidance to help its global teams reaffirm their commitment to safety through learning and team-building opportunities.
Tom Goodmanson, CEO of EcoOnline, commented, "By prioritising safety and collaboration, Menzies Aviation—together with EcoOnline—is setting new benchmarks for industry standards, ensuring a safer, more secure environment for employees and customers. It’s impressive that Graham still says, ‘more work is to be done,’ as it reflects Menzies’ commitment to continuous improvement."
Learn from Menzies’ safety success—explore the full case study here.
Visit ecoonline.com to immediately and positively impact your workplace safety and sustainability.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250116891021/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom